Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,339

Document Document Title
WO/2019/174533A1
A small molecule PD-1/PD-L1 inhibitor and the use thereof in drugs. Specifically, provided is a small molecule PD-1/PD-L1 inhibitor that is a chemical compound represented by formula (I), or a stereoisomer, geometric isomer, tautomer, ox...  
WO/2019/166962A1
Crystalline Form M1 of deutetrabenazine is provided along with methods of its preparation. Deutetrabenazine may be useful in the treatment of a VMAT2-mediated disease and thus crystalline Form M1 of deutetrabenazine may be incorporated i...  
WO/2019/153644A1
Provided are four crystal forms, A, B, C and D, of demethylene berberine hydrochloride, and a preparation method therefor, and further provided are X‑ray powder diffraction characteristic absorption peaks, infrared absorption peaks and...  
WO/2019/150387A1
A novel process for preparation of Deutetrabenazine ((RR, SS)-l,3,4,6,7-llb-Hexahydro-9,10-di(methoxy-d6)-3-(2-methylp ropyl)-2H- benzo [a] quinolizin-2-one) of formula I comprises of methylation of N-(2-(3,4-dihydroxy-phenyl)-ethyl)-for...  
WO/2019/142555A1
The present invention provides a luminescent film containing at least a phosphorescent compound and a fluorescent compound, wherein the convolution integral value J of the emission spectrum of the phosphorescent compound and the absorpti...  
WO/2019/129681A1
The present invention provides novel compounds having the general formula: wherein R1, R2, X, Y and A are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2019/104141A1
Salts and solid state forms of Valbenazine, including Valbenazine ditosylate, processes for preparation thereof, pharmaceutical compositions thereof, and uses thereof are disclosed.  
WO/2019/074492A1
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H- pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically accep...  
WO/2019/034031A1
The present invention provides a tetrahydroprotoberberine compound represented by general formula (I), an enantiomer, a diastereoisomer and a raceme thereof and a mixture thereof, a pharmaceutically acceptable organic or inorganic salt t...  
WO/2019/023189A1
Methods for treating leukemia, e.g., acute myeloid leukemia (AML), using inhibitors of essential genes including decapping enzyme scavenger (DCPS).  
WO/2018/224016A1
Disclosed is the use of berberine or a derivative thereof in preparing a myocardial perfusion imaging agent, specifically the use of 18F-labelled berberine or a derivative thereof in preparing a myocardial perfusion imaging agent. In vit...  
WO/2018/219356A1
The present invention relates to a fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the invention relates to a compound having Formu...  
WO/2018/222549A1
The present invention relates to deuterated compounds according to Formula I-A, Formula II-A, Formula II-D, and Formula III-A. These compounds can be used as PET imaging agents for evaluating Parkinson's Disease, Alzheimer Disease, and f...  
WO/2018/140095A3
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H- pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically accep...  
WO/2018/205987A1
The invention generally relates to solid forms of berberine ursodeoxycholate, and to pharmaceutical compositions, and methods of preparation and therapeutic use thereof. In particular, the invention relates to solid forms of berberine ur...  
WO/2018/203302A1
This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof that are useful as antibacterial agents. The compounds are useful as inhibitors of bacterial gyrase activity and of b...  
WO/2018/178251A1
The invention provides (+)-α-dihydrotetrabenazine succinate salt. Also provided are (+)-α-dihydrotetrabenazine succinate salt for use in medicine, pharmaceutical compositions comprising (+)-α-dihydrotetrabenazine succinate salt and a ...  
WO/2018/159849A1
Provided is: an azapyrene compound represented by general formula (1) [in the formula, R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, or a cyano group, R2 represents a divalent hydrocarbon group having six or ...  
WO/2018/159662A1
A compound according to the present invention, which has a structure represented by general formula AA is useful as a light emitting material. In the general formula, at least one of R1-R9 represents a substituent; each of Y1-Y3 represen...  
WO/2018/140096A1
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1, 3,4, 6,7,11 b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acc...  
WO/2018/140093A1
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H- pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically accep...  
WO/2018/140094A1
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy- 1,3,4,6,7,1 lb-hexahydro-2H-pyrido[2,l-a]isoquinolin-2-ol, or a pharmaceutically accep...  
WO/2018/140368A1
The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least o...  
WO/2018/130152A1
The present invention provides a compound of general formula I: formula I, in which R is any one of hydrogen, and C1-6 alkyl; R1 is any one of hydrogen, deuterium, halogen, C1-6 alkyl, C1-6 alkylamino, and C1-6 alkoxy; R2 is any one of h...  
WO/2018/068429A1
The present invention relates to a compound represented by structural formula I and a non-toxic, pharmaceutically acceptable salt thereof. R1, R2, R3, and R4 are each methyl (-CH3) or trideuteromethyl (-CD3), and at least one thereof is ...  
WO/2018/041873A1
The present invention relates to a process for synthesizing a compound of formula (la), or pharmaceutically acceptable salt or diastereomer thereof, which is useful for prophylaxis and treatment of a viral disease in a patient relating t...  
WO/2018/022282A1
The disclosure includes compounds of Formula (I), wherein Z1, Z2, Z3, X, R1, R2, R3, R4, R5, R6, and R7 are defined herein. Also disclosed is a method for treating HBV infection.  
WO/2018/019297A1
Disclosed is an isoquinolinone compound as shown in formula (I) or a stereoisomer, pharmaceutically acceptable salt, solvate or crystal thereof, and a preparation thereof and a use thereof in the preparation of drugs for treating or prev...  
WO/2018/006737A1
Disclosed are a mangiferin-6-O-calcium salt and a preparation method thereof, and the use of the mangiferin-6-O-calcium salt as an intermediate in the preparation of a mangiferin-6-O-berberine salt.  
WO/2018/001335A1
Crystal forms of NBI-98854 (of a structure as represented by formula I), a preparation method therefor and use thereof. The crystal forms of NBI-98854 are named as crystal form CS1 and crystal form CS2 respectively, and can be used in th...  
WO/2017/214683A1
The present invention provides a method for the treatment or prophylaxis of an ectoparasitic infestation, the method comprising the step of: contacting an external surface of an animal in need thereof with an effective amount of a berber...  
WO/2017/182916A1
The present invention provides process for preparation of dihydroxy benzoquinoline compound (III) comprising reacting dihydroxy isoquinoline compound (IV) or a salt thereof with (2-acetyl-4-methyl-pentyl)-trimethyl-ammonium iodide (V) an...  
WO/2017/106071A1
The present invention relates to spirocyclic quinolizine derivatives and pharmaceutically acceptable salts or prodrug thereof, compositions comprising at least one spirocyclic quinolizine derivative, and methods of using the spirocyclic ...  
WO/2017/103825A1
Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof (I), wherein R1-R5, and n are as defined in the specification, pharmaceutical compositions including a compound,...  
WO/2017/071576A1
The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of gene...  
WO/2017/067366A1
The invention relates to a method for extracting and refining alkaloid from ipecac. The method comprises the following steps: (1) extraction and concentration: grinding an ipecac medicinal material, adding an acidic methanol solution or ...  
WO/2017/066227A1
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...  
WO/2017/062804A1
The present invention provides compounds that can modulate the amount of Nav 1.7 protein, a key protein in pain signaling, that is present in the cellular surface and methods for using such compounds. In particular, compounds of the inve...  
WO/2017/027971A1
The present application is directed to transdermal formulations for the delivery of berberine compounds to a subject for the treatment of berberine-responsive diseases. In particular, the transdermal formulation comprises: (a) an aqueous...  
WO/2017/016921A1
The present invention relates to a new crystalline form of compound (I), (6S)-10-methoxy-6-isopropyl-9-(3-methoxypropoxy)-2-oxo-6,7-d ihydrobenzo[a]quinolizine-3- carboxylic acid and pharmaceutical compositions comprising the crystalline...  
WO/2017/016960A1
The present invention relates to a process for synthesizing a compound of formula (I), wherein R1 is C1-6alkoxy or haloC1-6alkoxy, R2 is C1-6alkyl unsubstituted or substituted by a substituent selected from C1-6alkoxy and haloC1-6alkoxy,...  
WO/2017/017042A1
The invention provides novel compounds having the general formula wherein R1 to R6, V, W, X and Y are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2016/199789A1
The present invention addresses the problem of efficiently synthesizing a trifluoromethyl substituted semisquarate in a short process, in order to manufacture trifluoromethyl compounds with various functionalities. A method was developed...  
WO/2016/161921A1
Conjugate compounds having at least one of a moiety derived from ursodeoxycholic acid, or eicosapentaenoic acid, or docosahexaenoic acid, or rhein, or R- (+) -α-lipoic acid, or ursolic acid, or corosolic acid, or hydroxycitric acid, or ...  
WO/2016/154527A1
The present invention relates to Phosphate Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present inve...  
WO/2016/143699A1
Provided are: a compound which is useful as an amyloid oxygenation catalyst that is applicable in vivo and is amyloid-selective, while being applicable not only to Aβ peptides but also to other amyloids; and a prophylactic and therapeut...  
WO/2016/127133A1
Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: wherein R1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMA...  
WO/2016/110250A1
Provided in the present invention are a mangiferin-6-O-berberine salt and a preparation method thereof. In addition, also provided is a use of the mangiferin-6-O-berberine salt as an AMPK activator for treating diabetes, etc.  
WO/2016/041515A1
Provided are compounds of formula (VI), a preparation method therefor and a pharmaceutical application of said compounds. The compounds can increase LDLR expression and reduce PCSK9 expression, and can be used for preventing and treating...  
WO/2016/041514A1
Disclosed are compounds of formula (V), a preparation method and a pharmaceutical application of said compounds. Specifically, disclosed are derivatives of compounds having the general formula (V), a preparation method and a use of said ...  

Matches 1 - 50 out of 1,339